Department of Epidemiology & Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA.
Prevention Insights, Department of Applied Health Science, Indiana University School of Public Health, Bloomington, IN, USA.
BMC Res Notes. 2021 May 20;14(1):195. doi: 10.1186/s13104-021-05601-z.
Persons who use opioids may be at elevated risk of harm from the coronavirus disease 2019 (COVID-19) pandemic, yet few data currently exist that can be used to examine this risk. As part of a rapid response survey, this study measured opioid users' perceptions of risk or harm from COVID-19, as well as potential changes in motivation to quit, frequency of use, and engagement with treatment. Data collected from Amazon's Mechanical Turk (n = 562) were analyzed.
Participants perceived modest risk elevation from COVID-19 due to their opioid use, and perceived moderate risk to themselves or their community from COVID-19. Since learning about COVID-19, 31.2% reported decreasing their opioid use, and 26.0% reported increased motivation to quit. Thirty-seven percent of participants reported both their use and motivation to quit stayed the same; 16.6% reported decreased use and increased motivation to quit. Participants who reported that their opioid use increased after learning about COVID-19, or whose motivation to quit opioids decreased, were more likely to also be engaged in treatment than those whose use or motivation stayed the same. These preliminary findings suggest that there likely is an association between COVID-19, opioid use, and treatment engagement that merits further in-depth investigation.
使用阿片类药物的人可能面临更高的感染 2019 年冠状病毒病（COVID-19）的风险，但目前几乎没有数据可以用来评估这种风险。作为快速反应调查的一部分，本研究衡量了阿片类药物使用者对 COVID-19 的风险或危害的认知，以及他们对停止使用阿片类药物的动机、使用频率和接受治疗的意愿的潜在变化。从亚马逊的 Mechanical Turk（n = 562）收集的数据进行了分析。
参与者认为他们的阿片类药物使用使他们感染 COVID-19 的风险略有增加，并且认为 COVID-19 对自己或社区有中度风险。自了解 COVID-19 以来，31.2%的人报告减少了阿片类药物的使用，26.0%的人报告了增加戒烟的动机。37%的参与者报告说他们的使用和戒烟的动机保持不变；16.6%的人报告使用减少，戒烟动机增加。与使用和戒烟动机保持不变的人相比，报告在了解 COVID-19 后阿片类药物使用增加或戒烟动机降低的参与者更有可能接受治疗。这些初步发现表明，COVID-19、阿片类药物使用和治疗参与之间可能存在关联，值得进一步深入调查。
